Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of Nordic Bioscience said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

image

Recommended for you

Advertisements

Quick Links

Market News

Gulshan Polyols rallies on fund buying

Reliance mid and small cap fund acquired 595,000 shares or 6.7% stake in Gulshan Polyols at price of Rs 250 per share.

Magma Fincorp surges ahead of board meet

The board of directors of the company will meet today to consider issue of equity shares on preferential basis.

Defence stocks in focus; Bharat Electronics, BEML gain 4%

Dynamatic Technologies, Astra Microwave, Pipavav Defence and Walchandnagar Industries up 2%-6% on the NSE.

Fortis Healthcare hits 52-week high on stake sale in Singapore hospital

The stock was up 4% at Rs 170 on the National Stock Exchange.

New LNG policy won't impact gas players much

Analysts don't see much benefits for GAIL and Petronet LNG as they will have to forego part of marketing margins and re-gasification tariffs

 

Back to Top